Geron Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
38,379.00
35,670.00
46.00
29,537.00
27,916.00
27,017
Depreciation, Depletion & Amortization
320.00
47.00
56.00
81.00
76.00
59
Other Funds
6,148.00
10,563.00
11,005.00
8,998.00
8,654.00
6,194
Funds from Operations
31,911.00
25,060.00
11,107.00
20,458.00
19,186.00
20,764
Changes in Working Capital
4,769.00
34,410.00
35,303.00
2,089.00
1,370.00
245
Net Operating Cash Flow
36,680.00
9,350.00
24,196.00
18,369.00
20,556.00
21,009
Capital Expenditures
3.00
131.00
90.00
57.00
-
Sale of Fixed Assets & Businesses
1,196.00
-
-
16.00
-
Purchase/Sale of Investments
19,862.00
78,302.00
164.00
8,804.00
22,970.00
Net Investing Cash Flow
21,054.00
77,904.00
74.00
8,763.00
22,970.00
Net Financing Cash Flow
6,553.00
98,360.00
2,575.00
1,169.00
1,111.00
Net Change in Cash
9,073.00
29,806.00
21,547.00
8,437.00
3,525.00
Free Cash Flow
36,683.00
9,219.00
24,286.00
18,426.00
20,556.00
Other Sources
-
529.00
-
-
-
Change in Capital Stock
6,553.00
98,360.00
2,575.00
1,169.00
1,111.00
Other Uses
1.00
-
-
-
-

About Geron

View Profile
Address
149 Commonwealth Drive
Menlo Park California 94025
United States
Employees -
Website http://www.geron.com
Updated 07/08/2019
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D.